The subpoena comes amid a wider probe by US regulators into steep increases in the prices of generic medicines in recent years.

Ranbaxy had sought the restraining order against Dr Reddy's Laboratories and US firm Endo International Plc

The move comes after Ranbaxy said that FDA had stripped the company of its tentative approval to launch the first copy of the drug.

Ranbaxy recouped its intraday losses and was trading 1.2 per cent higher at Rs 661.20. It hit a low of Rs 623 and a high of Rs 664.25 in tr...